Culture

Majority skeptical healthcare costs will fall anytime soon as Biden begins presidency

image: The survey found only 27% of Americans think the management of the pandemic is heading in the right direction - though it tops all other areas including the economy (23%), immigration reform (18%), climate change (15%) and the cost of healthcare, which only 8% of people think is going the right way.

Image: 
West Health-Gallup Healthcare Survey

WASHINGTON, D.C. and SAN DIEGO, CA -- In his inaugural address, President Joe Biden vowed that "help is on the way" to a nation grappling with a pandemic that has already claimed over 420,000 lives and counting. However, despite the promise of a better future, a new survey from West Health and Gallup finds Americans remain largely skeptical that issues as varied as managing the COVID-19 crisis, lowering healthcare costs, improving the economy, fixing immigration and addressing climate change, will improve anytime soon.

The findings from the monthly West Health-Gallup U.S. Healthcare Study are based on a nationally representative sample of 3,100 U.S. adults interviewed between Dec. 15, 2020, and Jan. 3, 2021, after the presidential election but before Biden took office and announced more detailed plans for his first 100 days.

The survey found only 27% of Americans think the management of the pandemic is heading in the right direction - though it tops all other areas including the economy (23%), immigration reform (18%), climate change (15%) and the cost of healthcare, which only 8% of people think is going the right way.

Notably, Americans are three times more likely to believe the COVID-19 pandemic is headed in the right direction than the cost of healthcare (27% vs. 8%), placing greater confidence in putting an end to a more than yearlong pandemic than reversing decades of high healthcare prices.

"Unfortunately, the only direction prices for healthcare and prescription drugs has gone is up," said Tim Lash, chief strategy officer of West Health, a nonprofit dedicated to issues related to aging and lowering healthcare costs. "Years of high prices from drug companies and broken promises from politicians to rein them in have understandably made people skeptical. Nonetheless, President Biden may have the best opportunity yet for meaningful reform."

The survey found when it comes to healthcare, the top three issues Americans want the U.S. government to focus on in President Biden's first 100 days are lowering insurance premiums (70%), cutting drug prices (66%) and reducing the uninsured rate (63%), followed by expanding care for older adults (58%) and childcare for working parents (55%). Across the board, Democrats were far more likely to place a higher priority on these issues than Republicans, particularly when it comes to lowering premiums (90% vs. 60%).

Optimism for success, however, does not run high. Only 28% report that they think the Biden Administration and new Congress will be able to enact policies that will bring down the cost of healthcare compared to 49% who are pessimistic, and 22% who have no opinion one way or the other. Similar margins were found for policies related to lowering the costs of prescription drugs. This may explain why 80% of respondents felt healthcare costs will only continue to rise over the next two years.

"President Biden and Congress can restore Americans' faith in the future of healthcare through quick, bold and decisive policy action that drives down costs. Years of promises to do so from previous politicians and policymakers have fallen flat and left Americans pessimistic and hurting from a high-priced health system," said Lash.

The task of lowering healthcare and prescription drug prices is as daunting as the situation is dire for many Americans. Over 500 drugs have already seen a median price hike of 4.8% this month alone. Meanwhile, according to the West Health-Gallup survey, more than one-quarter of adults report that in the last year there was at least one time when someone in their household did not pursue care due to its cost and some 15 million Americans (6%) know someone who died in the last five years because they couldn't afford treatment. Another 40% say they are but one negative health event away from filing for bankruptcy.

"Harnessing the rising costs of healthcare and prescription drugs are more important than ever to the American public," said Dan Witters, Gallup senior researcher. "And even as the federal government focuses on the pandemic response, dovetailing those efforts with alleviating the cost of care would certainly be expected to pay dividends with public opinion."

Credit: 
West Health Institute

Blood discoveries advance efforts to grow organs, battle cancer

Pioneering research into how our bodies manufacture the cells that make blood has moved us closer to regrowing tissues and organs. The findings also may let doctors grow the cells for transplantation into people to battle cancer, blood disorders and autoimmune diseases.

Researcher Karen K. Hirschi, PhD, of the Department of Cell Biology and the Robert M. Berne Cardiovascular Research Center at the University of Virginia School of Medicine, has developed a simple and efficient way to generate "hemogenic endothelial cells." These cells are the first step in the production line of blood cells, and Hirschi's new findings provide a blueprint for creating them outside the body.

"By studying how hemogenic endothelial cells develop normally, we gain insights needed to generate them in the lab," Hirschi said. "Now that we have established a method to produce human hemogenic endothelial cells outside of the body, we will continue to improve their production and function as we learn more about the mechanisms that promote their normal development."

Building Blood-Making Factories

Hirschi's latest work, published in a pair of scientific papers, offers important insights into how hemogenic endothelial cells form and how they ultimately give rise to the cells that directly manufacture blood throughout our lives.

Writing in the prestigious journal Science, she and her team reveal a key trigger that causes the endothelial cells to "transdifferentiate," or turn into blood-making factories, during embryonic development. These blood-making (i.e. hemogenic) endothelial cells generate hematopoietic stem and progenitor cells (HSPCs) that have long been used for the treatment of cancer and other diseases. Typically, they are taken from sources such as an individual's bone marrow, but doctors would like to be able to manufacture them quickly and easily for patients on demand. "Generating human hemogneic endothelial cells in the lab from each patient that needs HSPC is the first step toward patient therapies for blood disorders," Hirschi said.

In a paper published nearly simultaneously in Cell Reports, Hirschi unveils a blueprint for creating the hemogenic endothelial cells, the source of HSPCs, outside the body. The secret is a substance called retinoic acid. You may have heard of retinoic acid in association with beauty products, but in this case its responsibilities include triggering genes to cause "hematopoietic transition" - to put more vascular endothelial cells in the business of making blood by producing HSPCs.

The new insights provided by the work "will improve our ability to apply developmental insights to the generation of distinct endothelial cell subtypes for tissue engineering and regenerative medicine," the researchers write in their new paper. "In addition, our system could likely be developed further to optimize the generation of transplantable HSPCs from human hemogenic endothelial cells for clinical therapies."

The approach offers several advances over existing means, including being quicker and less expensive, the researchers note.

"We hope our continued efforts will move us closer to treating both vascular and blood disorders," Hirschi said. "These studies highlight the importance of basic cell and developmental biology research as a foundation for devising strategies for patient-specific clinical therapies."

Hirschi was recruited from Yale in 2019 to join the faculty in the Department of Cell Biology, which has long been interested in addressing how embryos develop and applying this basic knowledge to the repair and regeneration of damaged tissues and organs.

Credit: 
University of Virginia Health System

Voters perceive political candidates with a disability as qualified for elected office

Worldwide, over one billion people live with a disability. Historically, they have been discriminated against and stigmatized by society. To improve their rights, they should be included in political decision-making, yet there is a lack of political representatives who are known to have a disability. This under-representation may be due to several factors, including how voters perceive a political candidate with a disability. However, a new study published in Frontiers in Political Science, found for the first time that voters do not apply negative stereotypes when evaluating candidates with a disability. Rather, voters tend to perceive candidates with a disability as capable, honest, and caring.

Stereotypes as information short-cuts

To form an impression of others, and with a lack of motivation and resources to dig past the surface, we tend to use stereotypes of social groups as a basis of information. We do this in a political context as well. ''Stereotypes can serve as 'information shortcuts','' says Dr Stefanie Reher (University of Strathclyde, United Kingdom). ''Being aware of how stereotypes and assumptions might affect one's beliefs might help voters make more deliberate decisions''. She describes two types of stereotypes that might influence voters' perceptions of candidates with a disability: trait stereotypes, and stereotypes about competence and political beliefs of candidates. Trait stereotypes operate if voters perceive candidates with a disability as weaker or more vulnerable, but also as courageous or inspiring. Competence and beliefs stereotypes are at work if voters might perceive candidates with disabilities as more concerned with healthcare and minority rights, and less concerned with (for instance) defense.

The research

To study voters' perception of candidates with a disability, Reher surveyed 1,500 British participants. In the online survey, participants were presented with descriptions of two fictional candidates and were asked to assess them on several dimensions. The descriptions gave background information about the candidates: gender, age, ethnic background, profession, years of political activity, and previous experience of elected office. They either did not mention any disability or included one of three selected disabilities: paralysis below the waist, blindness, or deafness.

Overall, voters do not appear to apply negative trait stereotypes, such as incompetence and weakness, when assessing candidates with a disability. Particularly, voters perceive them as more caring, with a difference between 4% to 6% from non-disabled candidates, and more honest, with a difference between 3% to 5%. The findings also indicate that effects of competence and beliefs stereotypes are larger than trait stereotypes. Specifically, voters perceive candidates with a disability as more concerned with minority rights, healthcare, and social welfare, with a difference between 4% to 12%. Interestingly, candidates with a disability were perceived to be more left-wing, with a difference between 3% to 5%. ''The study suggests that voters consider disabled people as very capable of fulfilling the tasks of elected office,'' says Reher. ''In fact, it appears that the experience of being disabled is even seen as an asset in some policy domains, including social security and healthcare.''

Implications of the study

These findings have implications for governments and political parties. Reher continues, ''the finding that voters do not perceive disabled candidates as less competent than non-disabled candidates is very informative for governments and political parties, as well as aspiring disabled politicians themselves.'' The problem of under-representation in politics may not lay with voters. Instead, increasing different types of support for candidates with a disability is key. ''If voters do not support candidates less because they are disabled, this suggests that there are other factors preventing disabled people from reaching positions of political power'', Reher adds, ''including a lack of accessibility and financial support for reasonable adjustments, and potentially a hesitancy within parties to nominate disabled people as candidates.''

Credit: 
Frontiers

Drug prices in the U.S. are 2.56 times those in other nations

Prescription drug prices in the United States are significantly higher than in other nations, with prices in the U.S. averaging 2.56 times those seen in 32 other nations, according to a new RAND Corporation report.

The gap between prices in the U.S. and other countries is even larger for brand-named drugs, with U.S. prices averaging 3.44 times those in comparison nations.

The RAND study found that prices for unbranded generic drugs -- which account for 84% of drugs sold in the U.S. by volume but only 12% of U.S. spending -- are slightly lower in the U.S. than in most other nations.

"Brand-name drugs are the primary driver of the higher prescription drug prices in the U.S.," said Andrew Mulcahy, lead author of the study and a senior health policy researcher at RAND, a nonprofit, nonpartisan research organization. "We found consistently high U.S. brand name prices regardless of our methodological decisions."

The RAND analysis is based on 2018 data and provides the most up-to-date estimates of how much higher drug prices are in the U.S. as compared to other countries in the Organisation for Economic Co-operation and Development.

Researchers calculated price indexes under a wide range of methodological decisions. While some sensitivity analyses lowered the differences between U.S. prices compared to those in other nations, under all the scenarios overall prescription drug prices remained substantially higher in the U.S.

The analysis used manufacturer prices for drugs because net prices -- that is, the prices ultimately paid for drugs after negotiated rebates and other discounts are applied -- are not systematically available. Even after adjusting U.S. prices downward based on an approximation of these discounts to account for these discounts, U.S. prices remained substantially higher than those in other countries.

The one consistent area where prices were lower in the U.S. was generic drugs, where prices were 84% of the average paid in other nations.

"For the generic drugs that make up a large majority of the prescriptions written in the U.S., our costs are lower," Mulcahy said. "It's just for the brand name drugs that we pay through the nose."

The study found that among G7 nations, the United Kingdom, France and Italy generally have the lowest prescription drug prices, while Canada, Germany and Japan tend to have higher prices.

Although several prior studies compared drug prices in the United States with those in other countries, the most recent of these studies used data that are almost a decade old.

RAND researchers compiled their estimates by examining industry-standard IQVIA MIDAS data on drug sales and volume for 2018, comparing the U.S. to 32 nations that belong to the OECD. The data include most prescription drugs sold in the U.S. and comparison countries.

Researchers say that conducting such comparisons requires a variety of decisions and assumptions to calculate price indexes. The U.S. had consistently higher drug prices regardless of how the researchers calculated price indexes and treated outliers in the data.

The RAND team examined several subsets of prescription drugs, including brand-name originator drugs, unbranded generic drugs, biologics and nonbiologic drugs.

Some of the highest-priced drugs in the United States are brand-name drugs that can cost thousands of dollars per treatment and treat life-threatening illness such as hepatitis C or cancers.

"Many of the most-expensive medications are the biologic treatments that we often see advertised on television," Mulcahy said. "The hope is that competition from biosimilars will drive down prices and spending for biologics. But biosimilars are available for only a handful of biologics in the United States."

Researchers estimated that across all of the OECD nations studied, total drug spending was $795 billion. The U.S. accounted for 58% of sales, but just 24% of the volume.

Recent estimates are that prescription drug spending in the U.S. accounts for more than 10 percent of all health care spending. Drug spending in the U.S. jumped by 76% between 2000 and 2017, and the costs are expected to increase faster than other areas of health care spending over the next decade as new, expensive specialty drugs are approved.

Credit: 
RAND Corporation

COVID-19: 1 in 3 adults anxious, depressed

SINGAPORE, 28 January 2021 - One in three adults, particularly women, younger adults, and those of lower socioeconomic status, are experiencing psychological distress related to COVID-19, researchers at Duke-NUS Medical School, Singapore, reported in the journal PLOS ONE.

COVID-19 continues to pose serious threats to public health across the globe, and interventions such as lockdowns, quarantine and social distancing are having an adverse impact on the mental well-being of populations. The pandemic has escalated the burden of psychological distress, including anxiety, depression, post-traumatic stress and insomnia. However, the factors associated with increased susceptibility to psychological distress among adults in the general population during COVID-19 are not yet well known.

"Understanding these factors is crucial for designing preventive programmes and mental health resource planning during the rapidly evolving COVID-19 outbreak," explained Professor Tazeen Jafar, from the Health Services and Systems Research Programme at Duke-NUS, who led the study. "These factors could be used to identify populations at high risk of psychological distress so they can be offered targeted remote and in-person interventions."

Prof Jafar and her team performed a meta-analysis of 68 studies conducted during the pandemic, encompassing 288,830 participants from 19 countries, to assess risk factors associated with anxiety and depression among the general population. They found that, among the people most affected by COVID-19-related anxiety or depression, women, younger adults, individuals of lower socioeconomic status, those living in rural areas and those at high risk of COVID-19 infection were more likely to experience psychological distress.

The finding that women were more likely to experience psychological distress than men is consistent with other global studies that have shown that anxiety and depression are more common in women. "The lower social status of women and less preferential access to healthcare compared to men could potentially be responsible for the exaggerated adverse psychosocial impact on women," the researchers suggested. "Thus, outreach programmes for mental health services must target women proactively."

Younger adults, aged 35 and under, were more likely to experience psychological distress than those over the age of 35. Although the reasons for this are unclear, previous studies have suggested that it might be due to younger people's greater access to COVID-19 information through the media. This current study also confirmed that longer media exposure was associated with higher odds of anxiety and depression.

Other factors associated with psychological distress included living in rural areas; lower education, lower income or unemployment; and being at high risk of COVID-19 infection. However, having stronger family and social support and using positive coping strategies were shown to reduce the risk of psychological distress.

"The general public and healthcare professionals need to be aware of the high burden of psychological distress during the pandemic as well as education on coping strategies," Prof Jafar said. "Patients need to be encouraged to seek help, and access mental health counselling services with appropriate referrals."

Professor Patrick Casey, Senior Vice-Dean for Research at Duke-NUS, commented, "Even with the tremendous advances on the vaccine front, the world has come to realise that the COVID-19 pandemic will be with us for the long haul. Professor Jafar's study contributes valuable insights on the pandemic's psychological toll on populations around the world and highlights specific groups who may benefit from additional support, whether that is from their family or a healthcare provider."

Credit: 
Duke-NUS Medical School

Entrepreneurs benefit more from emotional intelligence than other competencies, such as IQ

Running a successful business has its challenges, but the COVID-19 pandemic has required many owners to pivot and look for new ways to operate profitably while keeping employees and consumers safe. Research from the Indiana University Kelley School of Business found that emotional intelligence - the ability to understand, use and manage emotions to relieve stress - may be more vital to a business' survival than previously thought.

"We found that entrepreneurs benefit much more from emotional competences than other competencies -- such as IQ -- due to high uncertainty and ambiguity that comes with the world of entrepreneurship and even more applicable in a crisis," said Regan Stevenson, assistant professor ?of entrepreneurship and management and the John and Donna Shoemaker Faculty Fellow in Entrepreneurship.

"Being an entrepreneur is not a 'traditional workplace setting.' If you are an entrepreneur, you know that managing your business can often feel like you are screaming alone on an emotional rollercoaster," Stevenson added. "The extreme nature of this setting makes one's ability to manage emotions and social connections critically more important, especially so during times of major disruption and crisis."

According to recent U.S. Bureau of Labor Statistics, about a fifth of all new businesses fail within their first two years and nearly half are shuttered within five years. More than a million U.S. companies with employees were shuttered in 2020, in large part due to the COVID-19 pandemic. The number of bankruptcies in 2020 and those expected this year likely will approach levels last seen during the worst quarter of the 2008-09 financial crisis.

"The extreme nature of the pandemic has made one's ability to manage emotions and social connections critically more important, especially so during these times of major disruption and crisis," said Ernest O'Boyle, associate professor of management and entrepreneurship and the Dale M. Coleman Chair in Management.

The research found that those with a higher emotional intelligence are better able to be self-motivated and have higher social skills - even under more normal circumstances.

"Emotional Intelligence is linked to social skills such as accurately perceiving other's needs, making good first impressions, and influencing others in interpersonal interactions. These skills are important for developing business networks, which can aid in signaling legitimacy and in acquiring resources," researchers wrote. "These skills can enhance creativity and opportunity recognition; aid decision making in emotionally turbulent situations and enable adaptive responses to unpredictable events."

Previous research has suggested that cognitive intelligence was a greater predictor of success among entrepreneurs. The two factors are seldom studied together.

"While IQ is unquestionably the better predictor of job performance and career success across all jobs and careers, within the domain of entrepreneurship, emotional intelligence was the stronger predictor of success," O'Boyle added. "Those with high emotional intelligence tended to be more successful as business leaders and enjoy success than in more typical jobs and careers."

Their findings are based on an empirical study of nearly 40 previous studies and a meta-analysis of 65,826 entrepreneurs observed through that research. Their paper, "What matters more for entrepreneurship success? A meta-analysis comparing general mental ability and emotional intelligence in entrepreneurial settings," appears in Strategic Entrepreneurship Journal.

Credit: 
Indiana University

Technology bolsters use of chia seeds to help improve health, slow signs of aging

image: An improved extraction method from Purdue University innovators involving chia seeds may provide new options for anti-aging products, nutritional foods and medicine capsules.

Image: 
Andrea Liceaga/Purdue University

WEST LAFAYETTE, Ind. - An improved extraction method involving chia seeds may provide new options for nutritional foods, medicine capsules and anti-aging products.

A Purdue University team has developed and patented the method to separate mucilage from chia seeds, yielding a protein-rich chia seed flour with improved bioactivity and functionality compared with conventional methods.

This work was supported by the USDA National Institute of Food and Agriculture, Hatch Act formula funds project 1019794.

Mucilage is a thick and gluey substance that surrounds chia seeds and can make processing the seeds for food or pharmaceutical uses much more difficult or nearly impossible.

"We are excited about our extraction method because it opens up so many new possibilities for using chia seeds," said Uriel Urbizo, a Ph.D. graduate student in Purdue's College of Agriculture involved in the innovation team led by Andrea Liceaga, an associate professor of food science. "Our process uses temperature, ultrasonication, and vacuum-assisted filtration to offer improved efficiency to save both time and money for companies processing chia seeds for nutritional, pharmaceutical, anti-aging or other applications."

Chia seeds have been used for centuries as protein sources, but Urbizo said conventional separation methods such as freeze-drying processes can be expensive, time-consuming, damage useful components of the seeds and decrease the total yield.

The Purdue researchers also tested the method they developed for potential applications such as using the mucilage and peptides to develop films that can be used in medicine capsules and anti-aging products, respectively.

"Our method offers an improved option for creating products that use components, primarily peptides, from the chia seeds to inhibit enzymes that play a role in the aging of skin," Liceaga said.

Credit: 
Purdue University

How coronavirus damages lung cells within mere hours

image: Human lung cells (blue) infected with SARS-CoV-2 (red). Courtesy of Hekman, et al.

Image: 
Courtesy of Hekman, et al.

What if scientists knew exactly what impact the SARS-CoV-2 virus had inside our lung cells, within the first few hours of being infected? Could they use that information to find drugs that would disrupt the virus' replication process before it ever gets fully underway? The discovery that several existing FDA-approved drugs--including some originally designed to fight cancer--can stop coronavirus in its tracks indicates the answer is a resounding yes.

A team of Boston University researchers--hailing from BU's National Emerging Infectious Diseases Laboratories (NEIDL), the Center for Regenerative Medicine (CReM) at BU's Medical Campus, and BU's Center for Network Systems Biology (CNSB)--embarked on a months-long, collaborative and interdisciplinary quest, combining multiple areas of expertise in virology, stem cell-derived lung tissue engineering, and deep molecular sequencing to begin answering those questions. They simultaneously infected tens of thousands of human lung cells with the SARS-CoV-2 virus, and then tracked precisely what happens in all of those cells during the first few moments after infection. As if that was not complicated enough, the team had to cool their entire high-containment research facility inside the NEIDL to a brisk 61 degrees Fahrenheit.

The result of that challenging and massive undertaking? The BU team has revealed the most comprehensive map to date of all the molecular activities that are triggered inside lung cells at the onset of coronavirus infection. They also discovered there are at least 18 existing, FDA-approved drugs that could potentially be repurposed to combat COVID-19 infections shortly after a person becomes infected. Experimentally, five of those drugs reduced coronavirus spread in human lung cells by more than 90 percent. Their findings were recently published in Molecular Cell.

Now, academic and industry collaborators from around the world are in contact with the team about next steps to move their findings from bench to bedside, the researchers say. (Although COVID-19 vaccines are starting to be rolled out, it's expected to take the better part of a year for enough people to be vaccinated to create herd immunity. And there are no guarantees that the current vaccine formulations will be as effective against future SARS-CoV-2 strains that could emerge over time.) More effective and well-timed therapeutic interventions could help reduce the overall number of deaths related to COVID-19 infections.

"What makes this research unusual is that we looked at very early time points [of infection], at just one hour after the virus infects lung cells. It was scary to see that the virus already starts to damage the cells so early during infection," says Elke Mühlberger, one of the study's senior investigators and a virologist at BU's NEIDL. She typically works with some of the world's most lethal viruses like Ebola and Marburg.

"The most striking aspect is how many molecular pathways are impacted by the virus," says Andrew Emili, another of the study's senior investigators, and the director of BU's CNSB, which specializes in proteomics and deep sequencing of molecular interactions. "The virus does wholesale remodeling of the lung cells--it's amazing the degree to which the virus commandeers the cells it infects."

Viruses can't replicate themselves because they lack the molecular machinery for manufacturing proteins--that's why they rely on infecting cells to hijack the cells' internal machinery and use it to spread their own genetic material. When SARS-CoV-2 takes over, it completely changes the cells' metabolic processes, Emili says, and even damages the cells' nuclear membranes within three to six hours after infection, which the team found surprising. In contrast, "cells infected with the deadly Ebola virus don't show any obvious structural changes at these early time points of infection, and even at late stages of infection, the nuclear membrane is still intact," Mühlberger says.

The nuclear membrane surrounds the nucleus, which holds the majority of a cell's genetic information and controls and regulates normal cellular functions. With the cell nucleus compromised by SARS-CoV-2, things rapidly take a bad turn for the entire cell. Under siege, the cells--which normally play a role in maintaining the essential gas exchange of oxygen and carbon dioxide that occurs when we breathe--die. As the cells die, they also emit distress signals that boost inflammation, triggering a cascade of biological activity that speeds up cell death and can eventually lead to pneumonia, acute respiratory distress, and lung failure.

"I couldn't have predicted a lot of these pathways, most of them were news to me," says Andrew Wilson, one of the study's senior authors, a CReM scientist, and a pulmonologist at Boston Medical Center (BMC), BU's teaching hospital. At BMC, Boston's safety net hospital, Wilson has been on the front lines of the COVID-19 pandemic since March 2020, trying to treat and save the sickest patients in the hospital's ICU. "That's why our [experimental] model is so valuable."

The team leveraged the CReM's organoid expertise to grow human lung air sac cells, the type of cell that lines the inside of lungs. Air sac cells are usually difficult to grow and maintain in traditional culture and difficult to extract directly from patients for research purposes. That's why much coronavirus research to date by other labs has relied on the use of more readily available cell types, like kidney cells from monkeys. The problem with that is kidney cells from monkeys don't react the same way to coronavirus infection as lung cells from humans do, making them a poor model for studying the virus--whatever is learned from them doesn't easily translate into clinically relevant findings for treating human patients.

"Our organoids, developed by our CReM faculty, are engineered from stem cells--they're not identical to the living, breathing cells inside our bodies, but they are the closest thing to it," says Darrell Kotton, one of the study's senior authors. He is a director of the CReM and a pulmonologist at BMC, where he has worked alongside Wilson in the ICU treating COVID-19 patients. The two of them often collaborated with Mühlberger, Emili, and other members of their research team via Zoom calls that they managed to join during brief moments of calm in the ICU.

In another recent study using the CReM's engineered human lung cells, the research team confirmed that existing drugs remdesivir and camostat are effective in combating the virus, though neither is a perfect fix for controlling the inflammation that COVID-19 causes. Remdesivir, a broad-use antiviral, has already been used clinically in coronavirus patients. But based on the new study's findings that the virus does serious damage to cells within hours, setting off inflammation, the researchers say there's likely not much that antiviral drugs like remdesivir can do once an infection has advanced to the point where someone would need to be put on a ventilator in the ICU. "[Giving remdesivir] can't save lives if the disease has already progressed," Emili says.

Seeing how masterfully SARS-CoV-2 commandeers human cells and subverts them to do the manufacturing work of replicating the viral genome, it reminded the researchers of another deadly invader.

"I was surprised that there are so many similarities between cancer cells and SARS-CoV-2-infected cells," Mühlberger says. The team screened a number of cancer drugs as part of their study and found that several of them are able to block SARS-CoV-2 from multiplying. Like viruses, cancer cells want to replicate their own genomes, dividing over and over again. To do that, they need to produce a lot of pyrimidine, a basic building block for genetic material. Interrupting the production of pyrimidine--using a cancer drug designed for that purpose--also blocks the SARS-CoV-2 genome from being built. But Mühlberger cautions that cancer drugs typically have a lot of side effects. "Do we really want to use that heavy stuff against a virus?" she says. More studies will be needed to weigh the pros and cons of such an approach.

The findings of their latest study took the four senior investigators and scientists, postdoctoral fellows, and graduate students from their laboratories almost four months, working nearly around the clock, to complete the research. Of critical importance to the team's leaders was making sure that the experimental setup had rock-solid foundations in mimicking what's actually happening when the SARS-CoV-2 virus infects people.

"Science is the answer--if we use science to ask the lung cells what goes wrong when they are infected with coronavirus, the cells will tell us," Kotton says. "Objective scientific data gives us hints at what to do and has lessons to teach us. It can reveal a path out of this pandemic."

He's particularly excited about the outreach the team has received from collaborators around the world. "People with expertise in supercomputers and machine learning are excited about using those tools and the datasets from our publication to identify the most promising drug targets [for treating COVID-19]," he says.

Kotton says the theme that's become obvious among COVID-19 clinicians and scientists is understanding that timing is key. "Once a patient is on a ventilator in the ICU, we feel limited in what we can do for their body," he says. "Timing is everything, it's crucial to identify early windows of opportunity for intervention. You can keep guessing and hope we get lucky--or you [do the research] to actually understand the infection from its inception, and take the guesswork out of drug development."

Credit: 
Boston University

An ancient economy

As one of the most experienced archaeologists studying California's Native Americans, Lynn Gamble(link is external) knew the Chumash Indians had been using shell beads as money for at least 800 years.

But an exhaustive review(link is external) of some of the shell bead record led the UC Santa Barbara professor emerita of anthropology to an astonishing conclusion: The hunter-gatherers centered on the Southcentral Coast of Santa Barbara were using highly worked shells as currency as long as 2,000 years ago.

"If the Chumash were using beads as money 2,000 years ago," Gamble said, "this changes our thinking of hunter-gatherers and sociopolitical and economic complexity. This may be the first example of the use of money anywhere in the Americas at this time."

Although Gamble has been studying California's indigenous people since the late 1970s, the inspiration for her research on shell bead money came from far afield: the University of Tübingen in Germany. At a symposium there some years ago, most of the presenters discussed coins and other non-shell forms of money. Some, she said, were surprised by the assumptions of California archaeologists about what constituted money.

Intrigued, she reviewed the definitions and identifications of money in California and questioned some of the long-held beliefs. Her research led to "The origin and use of shell bead money in California" in the Journal of Anthropological Archaeology.

Gamble argues that archaeologists should use four criteria in assessing whether beads were used for currency versus adornment: Shell beads used as currency should be more labor-intensive than those for decorative purposes; highly standardized beads are likely currency; bigger, eye-catching beads were more likely used as decoration; and currency beads are widely distributed.

"I then compared the shell beads that had been accepted as a money bead for over 40 years by California archaeologists to another type that was widely distributed," she said. "For example, tens of thousands were found with just one individual up in the San Francisco Bay Area. This bead type, known as a saucer bead, was produced south of Point Conception and probably on the northern [Santa Barbara] Channel Islands, according to multiple sources of data, at least most, if not all of them.

"These earlier beads were just as standardized, if not more so, than those that came 1,000 years later," Gamble continued. "They also were traded throughout California and beyond. Through sleuthing, measurements and comparison of standardizations among the different bead types, it became clear that these were probably money beads and occurred much earlier than we previously thought."

As Gamble notes, shell beads have been used for over 10,000 years in California, and there is extensive evidence for the production of some of these beads, especially those common in the last 3,000 to 4,000 years, on the northern Channel Islands. The evidence includes shell bead-making tools, such as drills, and massive amounts of shell bits -- detritus -- that littered the surface of archaeological sites on the islands.

In addition, specialists have noted that the isotopic signature of the shell beads found in the San Francisco Bay Area indicate that the shells are from south of Point Conception.

"We know that right around early European contact," Gamble said, "the California Indians were trading for many types of goods, including perishable foods. The use of shell beads no doubt greatly facilitated this wide network of exchange."

Gamble's research not only resets the origins of money in the Americas, it calls into question what constitutes "sophisticated" societies in prehistory. Because the Chumash were non-agriculturists -- hunter-gatherers -- it was long held that they wouldn't need money, even though early Spanish colonizers marveled at extensive Chumash trading networks and commerce.

Recent research(link is external) on money in Europe during the Bronze Age suggests it was used there some 3,500 years ago. For Gamble, that and the Chumash example are significant because they challenge a persistent perspective among economists and some archaeologists that so-called "primitive" societies could not have had "commercial" economies.

"Both the terms 'complex' and 'primitive' are highly charged, but it is difficult to address this subject without avoiding those terms," she said. "In the case of both the Chumash and the Bronze Age example, standardization is a key in terms of identifying money. My article on the origin of money in California is not only pushing the date for the use of money back 1,000 years in California, and possibly the Americas, it provides evidence that money was used by non-state level societies, commonly identified as 'civilizations.' "

Credit: 
University of California - Santa Barbara

Light pollution linked to preterm births, reduced birth weights

image: Babies born before term are at an increased risk for disability and death.

Image: 
UNSPLASH.COM

In a first-of-its-kind study, researchers discovered that light pollution leads to more than just wasted energy and washed-out starlight--it can increase the likelihood of a preterm birth by almost 13%. Laura Argys, professor of economics at the University of Colorado Denver, collaborated with scientists at Lehigh University and Lafayette College to produce this study.

Skyglow, the brightness of the night sky apart from discrete light sources such as the moon and visible stars, is one of the most pervasive forms of light pollution. When you have increased artificial brightness at night, coming from sources like streetlamps, outdoor advertising, and buildings, it reduces your ability to see the dark sky and individual stars. The study authors found that this can lead to health issues, particularly for pregnant women.

"We discovered that increased light pollution is linked to some pretty severe health challenges," said Argys. "In pregnant women, this includes a higher chance of delivering a baby with a reduced birth weight, a shortened gestational length, and an increase in preterm births."

According to the Center for Disease Control and Prevention (CDC), babies born too early have higher rates of death and disability. In 2018, preterm birth and low birth weight accounted for roughly 17% of infant deaths (deaths before one year of age).

According to study co-author and Lehigh University Professor Muzhe Yang, the biological clock in our bodies, known as circadian rhythms, are disrupted by light pollution. This, in turn, can cause sleep disorders that ultimately lead to adverse birth outcomes. Specifically, the likelihood of a preterm birth (a childbirth before 37 weeks) could increase by approximately 12.9% as a result of increased nighttime brightness.

"While greater use of artificial light at night (ALAN) is often associated with greater economic prosperity, our study highlights an often-neglected health benefit of 'darkness,'" said Yang. "The biological clock of a human body, like all lives on the earth, needs the 'darkness' as part of the light-dark cycle in order to effectively regulate physiological functions, such as sleep."

Argys and her team hope this research stimulates policy discussions when addressing light pollution regulations moving forward.

"While beneficial to the economy and society, ALAN's consequences are evident," said Argys. "Our study has important policy implications such as why we should minimize skyglow that is, for example, contributed by streetlights."

Credit: 
University of Colorado Denver

Osteoporosis, controversial fractures and various bone markers

Aging and lifestyle-related metabolic imbalances, such as hyperglycemia, hyperlipidemia, and oxidative-stress, cause the accumulation of advanced glycation end products (AGEs), including pentosidine (PEN, crosslinked type) and carboxymethyl-lysine (CML, non-crosslinked type). Osteoporosis is a widespread metabolic skeletal disease characterized by diminished bone mineral density (BMD) or bone strength, which increases the risk of fractures.

To date, the association of PEN and CML with osteoporotic fracture has been reported, and the accumulation of AGEs in bone tissue is thought to contribute to bone vulnerability via the deterioration of bone matrix proteins, especially collagen. However, the precise mechanisms of PEN and CML in fracture occurrence are unclear and remain controversial, while no studies to uncover why CML associates with fractures have been attempted. There have been no reports investigating the implications of both PEN and CML on bone metabolism, BMD, and fractures in the same patients.

Accordingly, a team of doctors from the Department of Orthopaedic Surgery, Shinshu University School of Medicine et al. examined the levels of urinary PEN and serum CML to assess and compare the impacts of those AGEs on bone status and prevalent osteoporotic fractures in a cohort of postmenopausal women.

The group found that PEN as well as CML was significantly associated with prevalent vertebral fracture in postmenopausal women. The mechanism of PEN might be independent of lumbar BMD, while that of CML could be BMD dependent. It would appear that PEN, a crosslinked type of AGE, associated independently with the occurrence of fracture via collagen network deterioration, leading to impaired bone quality without affecting BMD. On the other hand, as a non-crosslinked type of AGE, CML could have contributed to fracture occurrence through lowered BMD. Both AGEs therefore appear to impact bone status and health, although possibly via different mechanisms.

Corresponding author of the study, Associate Professor Yukio Nakamura states, this study assessed the impacts of both PEN and CML on a number of bone turnover-related markers, BMD, and fractures in the same postmenopausal outpatients who visited a primary care institution and demonstrated possible different mechanisms of those AGEs for the occurrence of fracture. Since this investigation was just a cross-sectional study, the team could not identify a causal relationship of AGEs with osteoporotic fractures.

Therefore, the pathophysiological importance of AGEs in fractures requires confirmation by a longitudinal prospective study design with general population, such as community-dwelling participants. Together with the laboratory experiments, we would like to uncover the epidemiologic and mechanistic associations between AGEs and fractures.

Finally, the team hopes to provide an effective intervention for the AGEs accumulation in bone tissue leading to bone health retention in the elderly.

Credit: 
Shinshu University

High schoolers discover four exoplanets through Harvard and Smithsonian mentorship program

image: A five-planet system around TOI-1233 includes a super-Earth (foreground) that could help solve mysteries of planet formation. The four innermost planets were discovered by high schoolers Kartik Pinglé and Jasmine Wright alongside researcher Tansu Daylan. The fifth outermost planet pictured was recently discovered by a separate team of astronomers. Artist rendering.

Image: 
NASA/JPL-Caltech

Cambridge, Massachusetts - They may be the youngest astronomers to make a discovery yet.

This week, 16-year-old Kartik Pinglé and 18-year-old Jasmine Wright have co-authored a peer-reviewed paper in The Astronomical Journal describing the discovery of four new exoplanets about 200-light-years away from Earth.

The high schoolers participated in the research through the Student Research Mentoring Program (SRMP) at the Center for Astrophysics | Harvard & Smithsonian. Directed by astrochemist Clara Sousa-Silva, the SRMP connects local high schoolers who are interested in research with real-world scientists at Harvard and MIT. The students then work with their mentors on a year-long research project.

"It's a steep learning curve," says Sousa-Silva, but it's worth it. "By the end of the program, the students can say they've done active, state-of-the-art research in astrophysics."

Pinglé and Wright's particular achievement is rare. High schoolers seldom publish research, Sousa-Silva says. "Although that is one of the goals of the SRMP, it is highly unusual for high-schoolers to be co-authors on journal papers."

With guidance from mentor Tansu Daylan, a postdoc at the MIT Kavli Institute for Astrophysics and Space Research, the students studied and analyzed data from the Transiting Exoplanet Survey Satellite (TESS). TESS is a space-based satellite that orbits around Earth and surveys nearby bright stars with the ultimate goal of discovering new planets.

The team focused on TESS Object of Interest (TOI) 1233, a nearby, bright Sun-like star. To perceive if planets were orbiting around the star, they narrowed in on TOI-1233's light.

"We were looking to see changes in light over time," Pinglé explains. "The idea being that if the planet transits the star, or passes in front of it, it would [periodically] cover up the star and decrease its brightness."

To the team's surprise, they discovered not one but four planets orbiting around TOI-1233.

"I was very excited and very shocked," Wright says. "We knew this was the goal of Daylan's research, but to actually find a multiplanetary system, and be part of the discovering team, was really cool."

Three of the planets are considered "sub-Neptunes," gaseous planets that are smaller than, but similar to our own solar system's Neptune. It takes between 6 and 19.5 days for each of them to orbit around TOI-1233. The fourth planet is labeled a "super-Earth" for its large size and rockiness; it orbits around the star in just under four days.

Daylan hopes to study the planets even closer in the coming year.

"Our species has long been contemplating planets beyond our solar system and with multi-planetary systems, you're kind of hitting the jackpot," he says. "The planets originated from the same disk of matter around the same star, but they ended up being different planets with different atmospheres and different climates due to their different orbits. So, we would like to understand the fundamental processes of planet formation and evolution using this planetary system."

Daylan adds that it was a "win-win" to work with Pinglé and Wright on the study.

"As a researcher, I really enjoy interacting with young brains that are open to experimentation and learning and have minimal bias," he says. "I also think it is very beneficial to high school students, since they get exposure to cutting-edge research and this prepares them quickly for a research career."

The SRMP was established in 2016 by Or Graur, a former postdoctoral fellow at the Center for Astrophysics |Harvard & Smithsonian. The program accepts about a dozen students per year with priority given to underrepresented minorities.

Thanks to a partnership with the City of Cambridge, the students are paid four hours per week for the research they complete.

"They are salaried scientists," Sousa-Silva says. "We want to encourage them that pursuing an academic career is enjoyable and rewarding--no matter what they end up pursuing in life."

Credit: 
Center for Astrophysics | Harvard & Smithsonian

Researchers reveal in-situ manipulation of active Au-TiO<sub>2</sub> interface

image: Geometric and electronic structure of Au-TiO2 interface under CO/O2 (A, C, E) and O2 environment (B, D, F)

Image: 
GAO Yi

An international joint research team from the Shanghai Advanced Research Institute of the Chinese Academy of Sciences, along with Zhejiang University and the Technical University of Denmark, reported an in-situ strategy to manipulate interfacial structure with atomic precision during catalytic reactions. Results were published in the latest issue of Science.

The interface between nanoparticles and substrates plays a critical role in heterogeneous catalysis because most active sites are located at the perimeter of the interface. It is generally believed that this interface is immobile and unchangeable, thus can hardly be adjusted in reactive environments. As a result, it has been challenging to promote catalytic activity through precise control of the interfacial structure.

In this study, the scientists first used environmental transmission electron microscopy to directly visualize the epitaxial rotation of gold nanoparticles on titanium dioxide (TiO2) surfaces during CO oxidation at the atomic level. A perfect epitaxial relationship was observed between Au nanoparticles and TiO2 (001) surfaces under an O2 environment in real time.

Theoretical calculations including density functional theory calculations and thermodynamics analysis were then carried out, indicating that the epitaxial orientation could be induced by changing O2 adsorption coverage at the perimeter interface. The Au nanoparticle was more stable with adsorption of more O2 molecules at the Au-TiO2 interface, but became less stable with the consumption of O2 with CO.

To exploit the promoted activity of Au-TiO2 interface, researchers conducted additional top-view observations and found that this configuration remained unchanged when cooling from 500 °C to 20 °C in CO and O2 reactive environments, showing the rotation of the Au nanoparticle was also temperature dependent in reaction conditions.

Taking advantage of the reversible and controllable rotation of the Au nanoparticle, the scientists achieved in-situ manipulation of the active Au-TiO2 interface at the atomic level by changing gas and temperature.

This study sheds light on real-time manipulation of catalytic interface structure in reaction conditions at the atomic scale, which may inspire future approaches to real-time design of the catalytic interface under operating conditions.

Credit: 
Chinese Academy of Sciences Headquarters

Rules of resistance against transgene silencing

image: KAUST scientists have designed silencing-resistant fluorescent proteins that can be localized to, for example, the cell membranes of C. elegans germ cells.

Image: 
© 2021 KAUST; Monika Priyadarshini.

Clear rules for engineering transgenes that can be inserted and propagated over multiple generations of nematodes include ways to protect inserted genes from the organism's natural defenses against foreign DNA. Developed by KAUST researchers, the rules have implications for many research fields, including gene therapy development.

Scientists often study biological processes, such as normal and mutant gene functions, in the worm Caenorhabditis elegans because it has many genes and molecular pathways in common with humans. Specific gene functions can be investigated by injecting DNA into the worm's reproductive organs, where it links into what is known as an extra-chromosomal array. This array is eventually incorporated into the nucleus, where it is duplicated and segregated into daughter cells. The injected genetic material is then potentially inherited across generations, which last only two days in C. elegans, allowing researchers to study gene functions over multiple generations in a short time period.

But C. elegans, like other multi-cellular organisms, has silencing mechanisms for recognizing and shutting down foreign DNA, which can hinder research efforts.

Scientists recently discovered that a class of noncoding DNA, called periodic A/T clusters (PATCs), can watermark their own genetic sequences to protect them from the natural silencing mechanisms of cells.

Bioengineer Christian Frøkjær-Jensen conducted investigations with students and researchers in his lab to develop rules for using PATCs, some gene regulators and reagents for persistent expression of transgenes in the C. elegans germline from simple extra-chromosomal arrays.

The protocol helps optimize transgenes and describes where PATCs should be inserted and the temperatures most suitable for propagating transgene strains, among other rules.

"Think of electrical circuits," says Frøkjær-Jensen. "Any electrical engineer can buy resistors and capacitors and be certain that these parts will behave in predictable ways when put together into a circuit. Our work aims to develop similar standards for genetic engineering in multicellular organisms. We also aim to freely distribute the necessary reagents for this process to the rest of the academic scientific community; we hope this will put KAUST on the map for biological engineering and synthetic biology."

Their investigations also led to the development of a web-based application for researchers to analyze their own DNA sequences for PATC watermarks. "PATCs can span large distances and rely on patterns that are not easily identifiable," explains Frøkjær-Jensen. "Previously, researchers needed to install specialized software to do this. Now, scientists can simply copy-paste their sequence files into our application to get an immediate analysis and graphical output." This will help scientists more easily use PATCs in their research and study their roles.

Credit: 
King Abdullah University of Science & Technology (KAUST)

Brain 3D genome study uncovers human-specific regulatory changes during development

image: The picture shows a meditating macaque, symbolizing the change of brain and mind during primate evolution.

Image: 
Image by LUO Xin et al

A team led by Prof. SU Bing from the Kunming Institute of Zoology (KIZ) of the Chinese Academy of Sciences (CAS), Prof. LI Cheng from Peking University, and Prof. ZHANG Shihua from the Academy of Mathematics and Systems Science of CAS has reported the highest resolution by far of the 3D genome of the primate brain, and demonstrated the molecular regulatory mechanisms of human brain evolution through cross-species multi-omics analysis and experimental validation. The study was published in Cell.

The unique pattern of human brain development stems from accumulated genetic changes during human evolution. Among the huge number of diverging genetic changes, only a small portion of the between-species changes have been functionally important. The challenge is to identify the causal changes responsible for the unique pattern of human brain development and their regulatory mechanisms. Macaque monkeys, genetically similar to humans, are the ideal model for studying the origin and developmental mechanisms of the human brain.

The genome of mammalian species including humans is about two meters long and is compiled in the nucleus with a diameter of only 10 micrometers. This nonrandom compilation is characterized by organized three-dimensional (3D) distribution, which is important for cell proliferation and differentiation during development. Recently, the invention of whole-genome chromosomal structure capture technology (referred to as Hi-C) provides a great opportunity for dissecting the fine-tuned organization of the genome during brain development.

In this study, the researchers conducted cross-species analyses of brain 3D genomes through cross-disciplinary collaboration.

They first constructed a high-resolution 3D chromatin structure map of the macaque fetal brain using the Hi-C technique. Reaching a 1.5 kb resolution, this Hi-C map represents the highest resolution of primate brains so far achieved, and it has become a useful omics dataset for revealing the 3D genome organization in detail. Meanwhile, the researchers generated a transcriptome map, a chromatin open region map and a map of the anchor protein CCCTC-binding factor (CTCF).

Based on these multi-omics data, the researchers constructed for the first time a fine map of the chromatin structure of the macaque fetal brain and identified the chromatin structure in different scales, including compartments, topologically associating domains (TADs) and chromatin loops. They also identified regulatory elements in the genome such as enhancers.

Using published human and mouse brain Hi-C data, they then performed a cross-species comparisons, and discovered many human-specific chromatin structural changes, including 499 human-specific TADs and 1266 human-specific loops. Notably, the human-specific loops were shown to be enriched with enhancer-enhancer interactions, representing the origin of a mechanism for fine-tuning brain development during human evolution.

Based on the analysis of single-cell transcriptome data on human brain development, the researchers observed that these human-specific loop-related genes are highly expressed in the subplate lamina, a transient zone of the developing brain critical for neural circuit formation and plasticity. The subplate lamina had been found to show an extradentary expansion compared to that of the macaque and mouse, and is about four times the thickness of the cortical plate. The subplate starts to decrease after birth and eventually disappears, and little is known about this transient zone. This finding provides the first evidence for the key role of the subplate in forming human-specific brain structures during development.

In addition, the researchers discovered that many human-specific mutations (e.g., point mutations and structural changes) are located in the TAD boundary and loop anchor regions, which may lead to the origin of novel binding sites of transcriptional factors and human-specific chromatin structures.

The researchers studied an example involving the EPHA7 gene, which is highly expressed in the subplate and is critical for neuronal dendrite development. The human-specific point mutations of EPHA7 lead to the formation of human-specific enhancers and loops. Through an experiment involving enhancer knockout in cell lines, they proved that human-specific EPHA7 enhancers can cause regulatory changes in EPHA7 expression and affect dendrite development.

This study sheds new light on the genetic mechanisms of human brain origin and serves as a valuable resource for 3D brain genomes.

Credit: 
Chinese Academy of Sciences Headquarters